Investigational drug · Phase 2
REGN5381
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Heart Failure.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "REGN5381"
First trial start
2022
Jun 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN5381", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN5381" as an intervention, largest first.
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05291546 · 93 participants · Start Apr 13, 2022 · Primary completion Apr 2, 2024
Drug: REGN9035; REGN5381 · For: Healthy Volunteers
Sites: Leuven, Belgium; Berlin, Germany
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04506645 · 90 participants · Start Sep 1, 2020 · Primary completion Dec 14, 2022
Drug: REGN5381 · For: Healthy
Sites: Ghent, Belgium; Leuven, Belgium
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06237309 · 89 participants · Start Apr 11, 2024 · Primary completion Sep 17, 2025
Drug: REGN5381; Placebo · For: Heart Failure
Sites: Phoenix, Arizona; Torrance, California; Miami, Florida · 44 sites in all
- REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge PressureCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05353166 · 59 participants · Start Jun 30, 2022 · Primary completion Jun 2, 2025
Drug: REGN5381; Matching Placebo · For: Heart Failure
Sites: Chisinau, Moldova
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06833190 · 34 participants · Start Apr 16, 2025 · Primary completion Oct 15, 2025
Drug: REGN5381; Placebo · For: Uncontrolled Hypertension
Sites: Huyton, United Kingdom; Salford, United Kingdom; Bury, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone.
Dunn ME, Kithcart A, Kim JH, et al. · Nature 2024
Also in development for Heart Failure
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- HiCM-188 therapyPhase 32 trials
HELP Therapeutics Co., Ltd. · Heart Failure
- Qishen Yiqi Dripping Pills 2 bagsPhase 32 trials
Tasly Pharmaceutical Group Co., Ltd · Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.